article Open AccessTop 1% cited

The RESTORE Study

Ophthalmology · 2011 · Vol. 118(4) · pp. 615–625

Paul Mitchell✉(Westmead Institute)Francesco Bandello(Vita-Salute San Raffaele University)Ursula Schmidt‐Erfurth(University of Vienna)Gabriele E. Lang(University Hospital Ulm)Pascale Massin(Hôpital Lariboisière)Reinier O. Schlingemann(Academic Center for Dentistry Amsterdam)Florian Sutter(University Hospital of Zurich)Christian Simader(Medical University of Vienna)Gabriela Burian(Novartis (Switzerland))Ortrud Gerstner(Novartis (Switzerland))Andreas Weichselberger(Novartis (Switzerland))

View via DOI Full-text PDF

Abstract

Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME. Visual acuity gains were associated with significant gains in VFQ-25 scores. At 1 year, no differences were detected between the ranibizumab and ranibizumab + laser arms. Ranibizumab monotherapy and combined with laser had a safety profile in DME similar to that in age-related macular degeneration.

Retinal Diseases and Treatments Glaucoma and retinal disorders Retinal Imaging and AnalysisMedicineRanibizumabOphthalmologyPro re nataVisual acuityLaser treatmentDiabetic retinopathyDiabetic macular edemaLaser coagulationRandomized controlled trial

MeSH terms

RanibizumabAntibodies, MonoclonalCombined Modality TherapyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyDouble-Blind MethodFemaleFluorescein AngiographyHumansMacular EdemaMaleMiddle AgedQuality of LifeSurveys and Questionnaires

Citations

1,316

FWCI

84.59

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Diabetic Retinopathy: Pathophysiology and Treatments